SG11202101072UA - Variant rnai against alpha-synuclein - Google Patents
Variant rnai against alpha-synucleinInfo
- Publication number
- SG11202101072UA SG11202101072UA SG11202101072UA SG11202101072UA SG11202101072UA SG 11202101072U A SG11202101072U A SG 11202101072UA SG 11202101072U A SG11202101072U A SG 11202101072UA SG 11202101072U A SG11202101072U A SG 11202101072UA SG 11202101072U A SG11202101072U A SG 11202101072UA
- Authority
- SG
- Singapore
- Prior art keywords
- synuclein
- rnai against
- against alpha
- variant
- variant rnai
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862714616P | 2018-08-03 | 2018-08-03 | |
PCT/US2019/044924 WO2020028816A1 (en) | 2018-08-03 | 2019-08-02 | Variant rnai against alpha-synuclein |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202101072UA true SG11202101072UA (en) | 2021-03-30 |
Family
ID=67587976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202101072UA SG11202101072UA (en) | 2018-08-03 | 2019-08-02 | Variant rnai against alpha-synuclein |
Country Status (15)
Country | Link |
---|---|
US (1) | US20210309999A1 (en) |
EP (1) | EP3830265A1 (en) |
JP (1) | JP2021534814A (en) |
KR (1) | KR20210062627A (en) |
CN (1) | CN112805382A (en) |
AR (1) | AR114540A1 (en) |
AU (1) | AU2019314529A1 (en) |
BR (1) | BR112021001980A2 (en) |
CA (1) | CA3108526A1 (en) |
CO (1) | CO2021002637A2 (en) |
IL (1) | IL280581A (en) |
MX (1) | MX2021001395A (en) |
SG (1) | SG11202101072UA (en) |
TW (1) | TW202022116A (en) |
WO (1) | WO2020028816A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112020005569A2 (en) * | 2017-09-22 | 2020-10-06 | Genzyme Corporation | interference rna (rnai) variant |
CA3171757A1 (en) * | 2020-03-18 | 2021-09-23 | Anastasia Khvorova | Oligonucleotides for snca modulation |
EP4359525A1 (en) * | 2021-06-21 | 2024-05-01 | uniQure biopharma B.V. | Gene constructs for silencing alpha-synuclein and uses thereof |
WO2023196862A1 (en) * | 2022-04-06 | 2023-10-12 | Genzyme Corporation | Targeted gene therapy for dm-1 myotonic dystrophy |
WO2024073609A2 (en) * | 2022-09-29 | 2024-04-04 | Atalanta Therapeutics, Inc. | Sirna compositions and methods targeting alpha-synuclein nucleic acids |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998010088A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6989264B2 (en) | 1997-09-05 | 2006-01-24 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
DE60039766D1 (en) | 1999-08-09 | 2008-09-18 | Targeted Genetics Corp | TEROLOGIC NUCLEOTIDE SEQUENCE FROM A RECOMBINANT VIRAL VECTOR BY STRUCTURE OF THE SEQUENCE IN A WAY THAT BASE COUNTERATIONS ARISE WITHIN THE SEQUENCE |
WO2001092551A2 (en) | 2000-06-01 | 2001-12-06 | University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
US20050137155A1 (en) * | 2001-05-18 | 2005-06-23 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA) |
US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
ES2439515T3 (en) | 2001-11-13 | 2014-01-23 | The Trustees Of The University Of Pennsylvania | Serotype rh10 of adeno-associated virus (AAV) |
WO2006119432A2 (en) | 2005-04-29 | 2006-11-09 | The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services | Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes |
WO2007120542A2 (en) | 2006-03-30 | 2007-10-25 | The Board Of Trustees Of The Leland Stanford Junior University | Aav capsid library and aav capsid proteins |
EP2164967B1 (en) | 2007-05-31 | 2015-07-08 | University of Iowa Research Foundation | Reduction of off-target rna interference toxicity |
GB0816778D0 (en) * | 2008-09-12 | 2008-10-22 | Isis Innovation | Gene silencing |
ES2605305T3 (en) | 2010-04-23 | 2017-03-13 | University Of Massachusetts | AAV vectors that target the CNS and their methods of use |
WO2012027713A2 (en) * | 2010-08-26 | 2012-03-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of snca |
US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
EP2640853B1 (en) * | 2010-11-17 | 2018-12-26 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
CN103502458B (en) | 2011-02-17 | 2016-11-16 | 宾夕法尼亚大学托管会 | For changing tissue specificity and improving compositions and the method for the gene transfer that AAV9-mediates |
CN114231563B (en) | 2014-05-02 | 2024-08-16 | 建新公司 | AAV vectors for retinal and CNS gene therapy |
PE20171382A1 (en) * | 2015-02-10 | 2017-09-15 | Genzyme Corp | ARNi VARIANT |
-
2019
- 2019-08-02 SG SG11202101072UA patent/SG11202101072UA/en unknown
- 2019-08-02 BR BR112021001980-4A patent/BR112021001980A2/en unknown
- 2019-08-02 JP JP2021529252A patent/JP2021534814A/en active Pending
- 2019-08-02 MX MX2021001395A patent/MX2021001395A/en unknown
- 2019-08-02 CN CN201980063972.6A patent/CN112805382A/en active Pending
- 2019-08-02 CA CA3108526A patent/CA3108526A1/en active Pending
- 2019-08-02 AR ARP190102204A patent/AR114540A1/en unknown
- 2019-08-02 AU AU2019314529A patent/AU2019314529A1/en active Pending
- 2019-08-02 KR KR1020217006255A patent/KR20210062627A/en unknown
- 2019-08-02 WO PCT/US2019/044924 patent/WO2020028816A1/en active Application Filing
- 2019-08-02 TW TW108127564A patent/TW202022116A/en unknown
- 2019-08-02 US US17/265,489 patent/US20210309999A1/en active Pending
- 2019-08-02 EP EP19752626.2A patent/EP3830265A1/en active Pending
-
2021
- 2021-02-02 IL IL280581A patent/IL280581A/en unknown
- 2021-02-26 CO CONC2021/0002637A patent/CO2021002637A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20210309999A1 (en) | 2021-10-07 |
KR20210062627A (en) | 2021-05-31 |
CN112805382A (en) | 2021-05-14 |
IL280581A (en) | 2021-03-25 |
JP2021534814A (en) | 2021-12-16 |
TW202022116A (en) | 2020-06-16 |
CO2021002637A2 (en) | 2021-07-30 |
MX2021001395A (en) | 2021-08-11 |
BR112021001980A2 (en) | 2021-05-04 |
EP3830265A1 (en) | 2021-06-09 |
AR114540A1 (en) | 2020-09-16 |
AU2019314529A1 (en) | 2021-03-25 |
WO2020028816A1 (en) | 2020-02-06 |
CA3108526A1 (en) | 2020-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL280581A (en) | Variant rnai against alpha-synuclein | |
IL273394A (en) | Variant rnai | |
GB201918689D0 (en) | n | |
PL3456736T3 (en) | Antibody variants | |
IL273351A (en) | Antibody variants | |
ZA202100322B (en) | Polytunnel structure | |
IL272951A (en) | Antibody variants | |
GB201813574D0 (en) | A1 | |
GB2576916B (en) | Polytunnel structure | |
GB201820913D0 (en) | St | |
GB2575634B (en) | Polytunnel structure | |
GB201813992D0 (en) | St | |
GB201813486D0 (en) | st | |
GB201813476D0 (en) | st | |
GB201813347D0 (en) | St | |
GB201813206D0 (en) | St | |
GB201811251D0 (en) | St | |
GB201809615D0 (en) | St | |
GB201809583D0 (en) | St | |
GB201809510D0 (en) | St | |
GB201809503D0 (en) | St | |
GB201818676D0 (en) | Polytunnel structure | |
GB201808169D0 (en) | St | |
GB201807984D0 (en) | St | |
GB201805817D0 (en) | St |